Thyroid Peroxidase Immunohistochemistry in Differential Diagnosis of Thyroid Tumors

2006 ◽  
Vol 17 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Svetlana Savin ◽  
Dubravka Cvejic ◽  
Tijana Isic ◽  
Ivana Petrovic ◽  
Ivan Paunovic ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Thyroid Peroxidase ◽  
Thyroid Tumors

scholarly journals Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors

Neoplasma ◽  
2020 ◽  
Vol 67 (01) ◽  
pp. 164-170
Author(s):  
D. Kalfert ◽  
M. Ludvikova ◽  
I. Kholova ◽  
J. Ludvik ◽  
O. Topolcan ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Thyroid Peroxidase ◽  
Thyroid Tumors ◽  
Combined Use ◽  
Galectin 3

Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors

Apmis ◽  
2011 ◽  
Vol 120 (5) ◽  
pp. 368-379 ◽  
Author(s):  
IVAN PAUNOVIC ◽  
TIJANA ISIC ◽  
MARIJA HAVELKA ◽  
SVETISLAV TATIC ◽  
DUBRAVKA CVEJIC ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Thyroid Peroxidase ◽  
Thyroid Tumors ◽  
Galectin 3

scholarly journals Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sergei E. Titov ◽  
Mikhail K. Ivanov ◽  
Pavel S. Demenkov ◽  
Gevork A. Katanyan ◽  
Eugenia S. Kozorezova ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Molecular Markers ◽  
Fine Needle Aspiration ◽  
Real Time Pcr ◽  
Thyroid Nodules ◽  
Nuclear Dna ◽  
Malignant Tumors ◽  
Needle Aspiration ◽  
Thyroid Tumors ◽  
Fine Needle

Abstract Background Analysis of molecular markers in addition to cytological analysis of fine-needle aspiration (FNA) samples is a promising way to improve the preoperative diagnosis of thyroid nodules. Nonetheless, in clinical practice, applications of existing diagnostic solutions based on the detection of somatic mutations or analysis of gene expression are limited by their high cost and difficulties with clinical interpretation. The aim of our work was to develop an algorithm for the differential diagnosis of thyroid nodules on the basis of a small set of molecular markers analyzed by real-time PCR. Methods A total of 494 preoperative FNA samples of thyroid goiters and tumors from 232 patients with known histological reports were analyzed: goiter, 105 samples (50 patients); follicular adenoma, 101 (48); follicular carcinoma, 43 (28); Hürthle cell carcinoma, 25 (11); papillary carcinoma, 121 (56); follicular variant of papillary carcinoma, 80 (32); and medullary carcinoma, 19 (12). Total nucleic acids extracted from dried FNA smears were analyzed for five somatic point mutations and two translocations typical of thyroid tumors as well as for relative concentrations of HMGA2 mRNA and 13 microRNAs and the ratio of mitochondrial to nuclear DNA by real-time PCR. A decision tree–based algorithm was built to discriminate benign and malignant tumors and to type the thyroid cancer. Leave-p-out cross-validation with five partitions was performed to estimate prediction quality. A comparison of two independent samples by quantitative traits was carried out via the Mann–Whitney U test. Results A minimum set of markers was selected (levels of HMGA2 mRNA and miR-375, − 221, and -146b in combination with the mitochondrial-to-nuclear DNA ratio) and yielded highly accurate discrimination (sensitivity = 0.97; positive predictive value = 0.98) between goiters with benign tumors and malignant tumors and accurate typing of papillary, medullary, and Hürthle cell carcinomas. The results support an alternative classification of follicular tumors, which differs from the histological one. Conclusions The study shows the feasibility of the preoperative differential diagnosis of thyroid nodules using a panel of several molecular markers by a simple PCR-based method. Combining markers of different types increases the accuracy of classification.

scholarly journals Pitfalls in Challenging Thyroid Tumors: Emphasis on Differential Diagnosis and Ancillary Biomarkers

2020 ◽  
Vol 31 (3) ◽  
pp. 197-217
Author(s):  
José Manuel Cameselle-Teijeiro ◽  
Catarina Eloy ◽  
Manuel Sobrinho-Simões
Keyword(s):  
Differential Diagnosis ◽  
Thyroid Tumors

Cytology of follicular thyroid tumors, quality assurance, and differential diagnosis

2010 ◽  
Vol 49 (1) ◽  
pp. 48-54 ◽  
Author(s):  
Miyoko MAEKAWA ◽  
Mitsuyoshi HIROKAWA ◽  
Yukari YANASE ◽  
Seiji KUMA ◽  
Akira MIYAUCHI
Keyword(s):  
Quality Assurance ◽  
Differential Diagnosis ◽  
Thyroid Tumors ◽  
Follicular Thyroid Tumors

Thyroid Tumors With a Follicular Growth Pattern: Problems in Differential Diagnosis

2006 ◽  
Vol 130 (7) ◽  
pp. 984-988 ◽  
Author(s):  
Saul Suster
Keyword(s):  
Differential Diagnosis ◽  
Papillary Thyroid Carcinoma ◽  
Growth Pattern ◽  
Medullary Carcinoma ◽  
Common Type ◽  
Thyroid Tumors ◽  
Papillary Thyroid ◽  
Follicular Growth ◽  
Follicular Variant ◽  
Diagnostic Categories

Abstract Tumors of the thyroid characterized by a follicular growth pattern constitute the most common type of lesion of this organ encountered by pathologists. The vast majority of such lesions do not pose difficulties for histopathologic interpretation. A subset of these tumors, however, can represent a serious challenge for diagnosis. Thyroid tumors with a follicular growth pattern include a broad range of lesions that range from benign, hyperplastic nodules to follicular adenomas to follicular carcinomas. In addition, other types of tumors belonging in separate diagnostic categories can also present histologically with a follicular growth pattern, including the follicular variant of papillary thyroid carcinoma and medullary carcinoma. The histologic features and diagnostic criteria used for distinguishing among these conditions can often be subtle and subjective.

scholarly journals Immunohistochemical Studies on Thyroid Peroxidase and Thyroglobulin in 13 Human Thyroid Tumors and 7 Graves' Goiters.

1993 ◽  
Vol 40 (6) ◽  
pp. 683-690 ◽  
Author(s):  
KAYO WATANABE ◽  
NARUMI KOIZUMI ◽  
OSAMU OZAKI ◽  
YUTAKA FUTAESAKU ◽  
TOICHIRO HOSOYA
Keyword(s):  
Human Thyroid ◽  
Thyroid Peroxidase ◽  
Thyroid Tumors ◽  
Immunohistochemical Studies

In Situ Hybridization and Immunohistochemistry Study of Thyroid Peroxidase Expression in Thyroid Tumors

Thyroid ◽  
2000 ◽  
Vol 10 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Catherine De Micco ◽  
Francis Kopp ◽  
Vassili Vassko ◽  
Michel Grino
Keyword(s):  
In Situ Hybridization ◽  
Thyroid Peroxidase ◽  
Thyroid Tumors

scholarly journals Immunohistochemical Expression of HBME-1, E-cadherin, and CD56 in the Differential Diagnosis of Thyroid Nodules

Medicina ◽  
2012 ◽  
Vol 48 (10) ◽  
pp. 74 ◽  
Author(s):  
Arturs Ozolins ◽  
Zenons Narbuts ◽  
Ilze Strumfa ◽  
Guna Volanska ◽  
Kaspars Stepanovs ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Follicular Carcinoma ◽  
Needle Aspiration ◽  
Thyroid Tumors ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Diagnostic Potential ◽  
Ancillary Test ◽  
Benign Thyroid ◽  
E Cadherin

Background and Objective. Distinction between benign and malignant thyroid tumors is essential for proper clinical management. The aim of this study was to evaluate the diagnostic potential of a set of 3 molecular markers in the differential diagnosis of thyroid tumors. Material and Methods. Immunohistochemistry for HBME-1, E-cadherin (E-CAD), and CD56 was carried out in 36 follicular adenomas, 77 colloid goiters, 36 papillary thyroid carcinomas, and 14 follicular carcinomas. Sixty-eight thyroid fine needle aspiration (FNA) cases confirmed by subsequent surgical resection specimens were selected. Immunocytochemistry for HBME-1, E-CAD, and CD56 was performed in these cases, including 25 papillary thyroid carcinomas, 1 follicular carcinoma, 22 follicular adenomas, and 20 colloid goiters. Results. PTC was characterized by a decreased expression of E-CAD and CD56 contrary to the surrounding benign thyroid tissues. There was no HBME-1 expression in benign thyroid tissues, but it was high in papillary thyroid carcinomas and weak in follicular adenomas. The expression of E-CAD and CD56 was significantly higher in follicular adenomas than in the surrounding thyroid tissues. Analyzing the FNA material, HBME-1 expression was documented in 96% of papillary thyroid carcinomas, but there was no expression in the benign lesions. E-CAD and CD56 expression was significantly weakened in papillary thyroid carcinomas, but enhanced in follicular adenomas. Conclusions. HBME-1 was found only in malignant lesions and can be considered the most sensitive, specific single marker in papillary thyroid carcinomas. CD56 and E-CAD can assist in the decision-making on the benign and malignant nature of the nodule. Immunocytochemistry is of value as an ancillary test to enhance the diagnostic accuracy of thyroid FNA samples.

scholarly journals The Utility of Serum Anti-thyroglobulin Antibody and Thyroglobulin in the Preoperative Differential Diagnosis of Thyroid Follicular Neoplasm

2021 ◽  
Author(s):  
Zhijiang Chen ◽  
Yinghe Lin ◽  
Shuiqing Lai ◽  
Peiqing Wang ◽  
Jinlian Li ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Risk Factor ◽  
Fine Needle Biopsy ◽  
Serum Markers ◽  
Thyroid Stimulating Hormone ◽  
Categorical Variables ◽  
Follicular Neoplasm ◽  
Thyroid Peroxidase ◽  
Follicular Thyroid Adenoma ◽  
Thyroglobulin Antibody

Abstract PurposeIt is challenging to distinguish follicular thyroid carcinoma (FTC) from follicular thyroid adenoma (FTA) before surgery due to the lack of malignant ultrasound features, the underdiagnosis by fine-needle biopsy, and the absence of definitive markers. We investigated whether thyroglobulin (Tg), anti-thyroglobulin antibody (TgAb), thyroid peroxidase antibodies (TPOAb), and thyroid stimulating hormone (TSH) could help differentiate FTC from FTA.MethodsA total of 319 patients with follicular neoplasms were included. We analyzed the serum markers as continuous and categorical variables between FTC and FTA. Also, we analyzed the prevalence of FTC in different serum markers groups.ResultsThe TgAb was a risk factor of FTC. Versus the TgAb group (≤11.68 IU/mL), OR of the group (11.69-30.50 IU/mL) and the group (＞30.50 IU/mL) were 2.206 (1.114-4.369, P=0.023) and 3.247 (1.684-6.260, P＜0.001), respectively. Versus the TgAb group (≤11.68 IU/mL), the malignant prevalence of the group (＞30.50 IU/mL) was higher (13.1% vs. 32.9%, P=0.001). In TgAb (-) patients, the Tg was another risk factor of FTC. Versus the Tg group (≤38.51 ng/mL), OR of the group (＞434.60 ng/mL) was 3.836 (1.625-9.058, P=0.002); the malignant prevalence of the group (＞434.60 ng/mL) was 47.2% and higher than other groups.ConclusionsThe TgAb and Tg may have utility in the preoperative differential diagnosis of follicular neoplasm. The higher TgAb and Tg were associated with higher malignant risk. Thus, we should be cautious of preoperative TgAb and Tg in follicular neoplasm.

Sign in / Sign up

Export Citation Format

Share Document